I remain optimistic that the pending audit of Amer
Post# of 148187
Possible revisit CD 10 and 12, NASH, nTNBC, HIV?
Might we resubmit request for approval based on updated data?
I any case, probable suit/settlement for damages could provide a windfall, based on strong evidence coming from our buddies at FDA.
We had to go after the data. It’s time for Leronlimab!